Candesartan AL

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Candesartan AL

Property Description
Active Ingredient (INN) Candesartan cilexetil (pro-drug)
Form Oral Tablet
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
Typical Use Scenario Used in the management of elevated blood pressure
Origin Synthetic Compound

What Kind of Medicine is Candesartan AL?

Candesartan AL is a prescription-only medicine that contains the active substance candesartan cilexetil, a synthetic compound typically administered as an oral tablet. This medication is specifically designed as a pro-drug because the ingested candesartan cilexetil is inactive and rapidly converts into the pharmacologically active compound, candesartan, during its absorption. This delivery method is a necessary differentiating factor to ensure effective systemic action of the active moiety. The final product, manufactured and marketed by pharmaceutical entities like AL, is a single-agent formulation.


What Pharmacological Class Does Candesartan Belong To?

Candesartan is classified as an Angiotensin II Receptor Blocker (ARB), or Angiotensin II Antagonist, placing it within the major grouping of cardiovascular agents and antihypertensive agents. This pharmacological class is widely clinically recognized for its ability to selectively modulate the body's blood pressure regulation system. Pharmacological studies support that candesartan has one of the highest binding affinities to the AT1 receptor within the ARB class, which contributes to its potency. This specialized mechanism principle makes it a highly effective tool for controlling high blood pressure.


What is the General Purpose of an Angiotensin II Antagonist?

The general therapeutic purpose of this antihypertensive agent is to aid in the long-term maintenance of healthy blood pressure and to support cardiovascular function. By preventing the powerful hormone Angiotensin II from binding to its key receptors, candesartan effectively stops the signal that would otherwise cause vasoconstriction (narrowing of blood vessels). The resulting physiological action is that the blood vessels relax and widen. This fundamental effect provides a benefit in typical use scenarios, such as reducing the elevated resistance in blood vessels associated with chronic hypertension, which ultimately reduces the strain on the heart and supports overall blood flow.

Advertisements

What side effects are possible with Candesartan AL?

Possible Side Effects and Safety Information

The safety profile of Candesartan AL is formally documented by regulatory authorities, classifying possible effects by frequency and the affected body system. Adverse reactions are grouped into categories such as Common (meaning they occur frequently in clinical trials) and Very Rare (based on post-marketing surveillance reports).

Commonly Documented Adverse Reactions

Adverse effects reported frequently in studies for hypertension include dizziness, headache, upper respiratory tract infection, pharyngitis, rhinitis, and back pain. These effects are classified as Common in the official prescribing information.

Serious Adverse Reactions and System-Organ Effects

Regulatory documents also list rare but serious adverse reactions, including Angioedema (swelling of the face or throat) and potentially fatal Fetal Toxicity if used during the second or third trimester of pregnancy. Effects are also classified by system, noting Blood and Lymphatic System Disorders (e.g., Agranulocytosis), Hepatobiliary Disorders (e.g., Hepatitis), and Renal and Urinary Disorders (e.g., Acute Renal Failure), which are typically reported as Very Rare.

Population-Specific Safety Constraints

The use of Candesartan AL is subject to specific constraints based on population. It is contraindicated during the later stages of pregnancy and should not be used in children under one year of age. For patients with chronic heart failure, the risk of hypotension (low blood pressure) and hyperkalemia (high potassium levels) is noted to be higher, particularly at the start of therapy or during dose increases. Furthermore, the medicine is contraindicated in individuals with severe hepatic impairment.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Candesartan cilexetil overdose is primarily defined by an extreme exaggeration of the drug's intended effect.


Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Overdose is expected to result in symptomatic hypotension (profound low blood pressure) and dizziness.
Physiological systems affected Primarily the Cardiovascular system, potentially manifesting as tachycardia (fast heart rate) or bradycardia (slow heart rate).
Population-specific overdose notes Volume-depleted patients may experience enhanced hypotension. Heart failure patients may be more susceptible to severe complications.
When immediate medical help is required Seek emergency medical attention or call the Poison Help line immediately upon suspected overdose.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Overdose may be associated with life-threatening outcomes such as syncope (fainting) or, rarely, acute renal failure due to severe hypotension.
Antidote availability No specific antidote is known. The compound cannot be removed from the circulation by hemodialysis due to high plasma protein binding.

Official Overdose Statements

  • Overdose may present with exaggerated effects, primarily symptomatic hypotension, dizziness, tachycardia, or bradycardia.
  • Management is symptomatic and supportive, and treatment of symptomatic hypotension involves prompt administration of intravenous volume expanders.

Connection to the overall overdose profile: Regulatory documents define the overdose profile based on an exaggeration of its core activity, leading to profound low blood pressure and associated cardiovascular signs. Since no specific antidote is known, the official response requires immediate medical assistance to initiate symptomatic and supportive treatment, including close observation and measures to correct hypotension.

Advertisements

Therapeutic Uses of Candesartan AL

What Candesartan AL Treats: Main Uses and Benefits

Candesartan AL is commonly used across major cardiovascular disease therapeutic domains. This medication generally helps address conditions marked by increased physiological stress on the circulatory system, such as systemic high blood pressure (hypertension) and symptomatic chronic heart failure. It is relevant in clinical settings that involve chronic systemic imbalance.

The primary therapeutic benefit relates to reducing cardiovascular risk, which may help manage the probability of complications associated with chronic, elevated pressure. For patients with heart failure, it assists with managing troublesome symptoms that interfere with daily functioning, such as difficulty breathing or swelling.

“This therapy contributes to supporting organ health over time, particularly for at-risk patient groups with conditions like hypertension and diabetes.”

It is generally used to help with managing conditions that involve high blood pressure and functional limitations, assisting with maintaining functional stability during activities and supporting the patient's day-to-day comfort.


Quick Fact: Support for Functional Limitations

Candesartan AL is commonly used to support patients with chronic heart failure experiencing symptoms that interfere with daily functioning and physical restriction.

Regulatory References

  1. NIH DailyMed Candesartan Indications
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Candesartan AL

Official regulatory documents define strict population eligibility for Candesartan cilexetil, detailing who is approved for use and who must not take the medicine.

Contraindications and Prohibited Use

Candesartan AL is contraindicated (must not be used) in several patient groups:

  • Pregnancy: Prohibited during the second and third trimesters. Discontinuation is required as soon as pregnancy is detected.
  • Age: Children aged below 1 year must not use this medicine for hypertension treatment.
  • Organ Function: Patients with severe hepatic impairment and/or cholestasis are contraindicated.
  • Hypersensitivity: Patients with known hypersensitivity to candesartan cilexetil or any excipients.
  • Comorbidity: Concomitant use with Aliskiren-containing products is prohibited in patients with Diabetes Mellitus or renal impairment (GFR < 60 mL/min/1.73m²).

Approved and Restricted Populations

Adults are approved for use in hypertension and heart failure. Children aged 1 to < 17 years are approved for hypertension. Use is not recommended for nursing mothers or patients with Primary Hyperaldosteronism.

Certain populations require special consideration and a potential lower starting dose:

  • Patients with severe renal impairment.
  • Patients with moderate hepatic impairment.
  • Patients with intravascular volume depletion.
Advertisements

What should I know about interactions with other medicines?

Candesartan AL Interactions with other medicines and products

The official interaction profile for Candesartan AL is primarily defined by pharmacodynamic additive effects that influence blood pressure regulation and fluid balance, as stated in regulatory documents.


Interaction-Related Restrictions

  • Dual blockade of the Renin-Angiotensin System (RAS): Co-administration with Aliskiren is contraindicated for specific populations, including patients with diabetes mellitus or those with moderate to severe renal impairment (Glomerular Filtration Rate < 60 mL/min).
  • Combinations with other RAS blockers, such as ACE inhibitors, are associated with an increased risk of hypotension, hyperkalemia, and changes in renal function.
  • Agents that increase serum potassium (e.g., potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes) pose an additive risk for hyperkalemia.

Official Interaction Statements

  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors, may attenuate the antihypertensive effect and may cause deterioration of renal function. This risk is noted as being heightened in the elderly or volume-depleted patients.
  • Co-administration with Lithium has been reported to increase serum concentrations and toxicity due to reduced clearance.
  • Alcohol consumption may potentiate the risk of orthostatic hypotension.
  • From a metabolic perspective, Candesartan AL is not significantly metabolized by the Cytochrome P450 system, and no major CYP-mediated interactions are expected. Food does not affect its bioavailability, and no mandatory timing separation rules are documented.

Connection to the overall interaction profile:

The regulatory documents primarily define the interaction structure through pharmacodynamic constraints that target the cardiovascular and renal systems. All label-based constraints and warnings are tied to specific drug combinations or officially defined population-based conditions.

Advertisements

Mechanism of Action

How Candesartan AL Works

Candesartan AL is a prodrug, candesartan cilexetil, which is rapidly hydrolyzed to its active component, candesartan, during absorption. Candesartan functions as a selective antagonist by acting within the domain of receptor-mediated signaling in the Renin-Angiotensin-Aldosterone System (RAAS).

Selective Angiotensin II Receptor Blockade

The active compound selectively binds to and blocks the Angiotensin II type 1 ( AT1) receptors found in vascular smooth muscle, adrenal glands, and other tissues. This interaction prevents endogenous Angiotensin II—a critical mediator of vascular tone—from binding to the AT1 receptor and initiating its downstream signaling effects.

Downstream Physiological Modulation

By antagonizing the AT1 receptor, candesartan modifies the molecular cascade that regulates systemic fluid and vascular homeostasis. This mechanism results in the suppression of vasoconstriction and the inhibition of aldosterone release from the adrenal cortex. These pathway adjustments lead to a decrease in systemic vascular resistance and an increase in renal excretion of sodium and water.

Advertisements

Dosage and Administration Information

Candesartan AL is primarily administered via the oral route, typically as a tablet in strengths ranging from 4 mg to 32 mg of candesartan cilexetil. The medicine is generally taken once daily and may be administered with or without food. It is intended for long-term maintenance therapy, with the maximal blood pressure effect usually observed within four to six weeks of starting treatment.


The official dosing regimens establish distinct patterns for chronic conditions:

Indication Initial Dose (Adults) Maintenance Range/Target Frequency Pattern
Hypertension 16 mg once daily 8 mg to 32 mg total daily dose Once daily, or divided twice daily
Heart Failure 4 mg once daily Target of 32 mg once daily Dose doubled at 2-week intervals

These regimens require specific adjustments for certain populations. For patients with severe renal impairment or moderate hepatic impairment, a lower initial dose of 4 mg is typically considered. Older adults (aged 65 and over) typically do not require an initial dose change. If a dose is missed, standard practice is to take it if remembered within 12 hours; otherwise, the missed dose should be skipped. This standardized protocol ensures consistency in the initiation and ongoing use of candesartan cilexetil.

Advertisements

Recent Clinical Evidence

Candesartan AL: Recent Clinical Evidence


Treatment of Hypertension

Candesartan, as an Angiotensin II Receptor Blocker (ARB), has been extensively studied for its efficacy in managing high blood pressure (hypertension). Clinical trials consistently show that candesartan effectively lowers systolic and diastolic blood pressure across various adult populations. Research has explored its use as both a stand-alone treatment (monotherapy) and in combination with other anti-hypertensive agents, such as thiazide diuretics, often achieving target blood pressure goals.

Use in Heart Failure

Evidence from large-scale clinical programs, such as the Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity (CHARM) program, has examined the role of candesartan in treating chronic heart failure, particularly in patients who cannot tolerate or who remain symptomatic despite standard therapies.

  • Key Findings
    • Studies observed changes in cardiovascular mortality and hospital admissions related to heart failure across the trial cohorts.
    • Candesartan was investigated for its potential to improve left ventricular function and reduce the risk of cardiovascular events in this patient group.

Tolerability Profile Summary

Clinical data indicates that candesartan is generally well-tolerated. Common adverse events observed in research settings often mirror those of the ARB class and may include headache or dizziness. Serious adverse effects are uncommon but may involve angioedema. Research confirms that candesartan offers a benefit over placebo in reducing blood pressure and supporting heart function in appropriate populations, as demonstrated by the clinical trial results.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Candesartan AL (FAQ)


Q: How quickly should I expect Candesartan AL to start lowering my blood pressure?

According to official prescribing information, most of the blood pressure-lowering effect is often noticed within two weeks of starting treatment. However, the maximum effect on blood pressure is typically reached after four to six weeks of consistent daily use.


Q: Is it okay to stop taking Candesartan AL suddenly?

Official drug documentation does not contain specific guidance on the effects of suddenly stopping this medication, as it is intended for long-term maintenance of chronic conditions. The decision to stop or change treatment is typically made in consultation with a physician.


Q: Are there any specific foods I should avoid when on Candesartan AL?

Regulatory warnings mention that this type of medicine can increase blood potassium levels. Therefore, regulatory information notes that potassium-containing salt substitutes or potassium supplements should be avoided unless specifically directed by a healthcare professional.


Q: Why is it important to monitor potassium levels while using Candesartan AL?

Candesartan is associated with a risk of elevated blood potassium levels, known as hyperkalemia. Monitoring is required to manage the risk of elevated potassium, which can affect heart function.


Q: What is the connection between Candesartan AL and Angiotensin II?

Candesartan AL is classified as an Angiotensin II Receptor Blocker (ARB). It works by blocking the action of the hormone Angiotensin II on a specific receptor, which prevents the hormone from causing blood vessels to narrow. This resulting relaxation of the blood vessels helps to lower blood pressure.


Q: Why is Candesartan AL contraindicated for people with specific kidney artery issues?

Regulatory documents state that patients whose kidney function relies on the activity of the renin-angiotensin system, such as those with renal artery stenosis, are at risk. Taking Candesartan AL may cause a dangerous decrease in kidney function in these specific, susceptible patient groups.


Q: How does Candesartan AL compare to ACE inhibitors in terms of common side effects?

Clinical studies often highlight that the incidence of cough with candesartan is reported to be similar to that seen with a placebo. This is a factor noted in contrast to other types of blood pressure medications, like ACE inhibitors, where a persistent dry cough is a more frequently reported side effect.


Q: What happens if I take a double dose of Candesartan AL by mistake?

Official information regarding overdosage indicates that taking too much is most likely to cause symptoms of severe low blood pressure (hypotension). These effects may include feeling dizzy or experiencing a fast heart rate. Symptoms related to an overdose require evaluation by a healthcare professional.


Q: How is Candesartan AL different from Losartan or Valsartan?

Candesartan AL, Losartan, and Valsartan all belong to the same pharmacological class: Angiotensin II Receptor Blockers (ARBs). They share the core function of blocking the same receptor. Differences between them exist in their exact chemical structure, their required dosages, and their duration of action in the body.


Q: Does Candesartan AL help with high blood pressure only?

No. According to official drug labels, Candesartan cilexetil is approved for the treatment of hypertension (high blood pressure) and also for the treatment of heart failure in adult patients.


Q: Is weight gain a common side effect of Candesartan AL?

Official drug documents do not list weight gain as a common adverse reaction that occurred frequently in clinical trials. It is typically included under less frequent categories of side effects.


Q: Does Candesartan AL affect kidney function?

The medicine can be associated with changes in kidney function, including rare reports of acute renal failure in specific patients. The official labeling indicates that kidney function markers, such as creatinine and BUN, are monitored periodically during treatment.


Q: Is it common to have a dry cough with Candesartan AL?

Official European drug documentation lists cough as a Very Rare side effect. This means it is reported to occur in fewer than 1 in 10,000 patients.


Q: Does Candesartan AL cause sexual side effects?

Official safety data has included reports of decreased sexual desire or ability under less frequent categories in the post-marketing surveillance reports. These types of effects are not listed among the commonly reported side effects in clinical trials.


Q: Does Candesartan AL affect my sleep?

Official safety reports have listed effects such as insomnia or sleep disorder as very rare side effects, meaning they occur with very low frequency in relation to the drug.


Q: What is the maximum dose of Candesartan AL described in official documents?

The maximum recommended daily dose for hypertension is generally 32 mg. Official guidance states that doses higher than 32 mg are not reported to show a greater benefit for lowering blood pressure.


Q: Does Candesartan AL require regular blood tests?

Yes. The official label recommends that both kidney function (including BUN and creatinine) and serum potassium levels should be monitored periodically with blood tests for patients taking this medicine.


Q: Is Candesartan AL a generic drug?

The active ingredient, candesartan cilexetil, is available as a generic drug in various formulations. It is also available under the original brand name product, ATACAND.


Q: Are there different brand names for Candesartan AL?

Yes, the active substance candesartan cilexetil was originally marketed under the brand name ATACAND in the United States and other regions. It is also widely available as numerous different generic products.


Q: Does Candesartan AL contain sulfites or lactose?

The formulation of the original brand-name product ATACAND lists lactose as one of its inactive ingredients. Sulfites are not typically listed as an excipient.


Q: Can Candesartan AL be split or crushed?

The official product characteristics for certain tablets indicate that the medicine can be divided into equal doses, suggesting it is safe to split the tablet. Instructions for crushing the tablets are not generally included in the official documentation.


Q: Does Candesartan AL make me tired or fatigued?

While fatigue is not listed as a common adverse reaction, symptoms like dizziness or tiredness may be experienced as a result of the blood pressure-lowering effect of the medicine. These effects are noted in official information as potential signs of low blood pressure.


Q: How long does Candesartan AL stay in my system?

The active compound, candesartan, is characterized by its elimination half-life, which is approximately nine hours. This pharmacokinetic information helps determine the appropriate daily dosing schedule.


Q: Does taking Candesartan AL affect my ability to drive or operate machinery?

Official warnings indicate that caution should be exercised when driving or operating machinery. This is because the medicine can cause side effects such as dizziness or lightheadedness, which may affect attention and coordination.


Q: Does Candesartan AL interact with herbal supplements like St. John's wort?

Candesartan is not significantly metabolized by the Cytochrome P450 system, which is a major pathway for many drug-herbal interactions. Therefore, major interactions of this type are not generally expected or documented in official labeling.


Q: Does Candesartan AL increase sensitivity to the sun?

For the single-agent product, dermatologic reactions like rash and hives are noted as very rare side effects. Photosensitivity (increased sun sensitivity) is a recognized risk associated with the diuretic often used in combination with candesartan, but not strongly associated with the candesartan component itself.

Advertisements

How should Candesartan AL be stored and disposed of?

How to Store and Dispose of Candesartan AL

Candesartan AL tablets must be stored at room temperature, away from excess heat and moisture. The medication should be kept in the container it came in and the cap must be kept tightly closed. Officially, the product should not be stored in the bathroom. For certain packaging types (e.g., HDPE bottles), the shelf life after first opening is specifically limited to 3 months.


Storage and Waste Handling

For child safety, the medicine must be stored out of the sight and reach of children and the safety cap kept locked. Disposal of any unused or expired product must be performed in accordance with local requirements. The medication should not be flushed down the toilet or poured down a drain; using a medicine take-back program is the preferred disposal method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Candesartan AL found in:

A-Z Index: